Question 1

What are the potential benefits of taking aspirin after my surgery?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

Question 2

How will I know if I qualify for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I be aware of while taking aspirin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects from the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there other treatment options I should consider instead of this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk clinical trial (NCT02945033). Contact the study team or your healthcare provider for specific answers.

What this study is about